Telomir Pharmaceuticals Inc. (TELO) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, TELO scores 34 out of 100, earning a letter grade of E and the verdict "Roarable Strong Sell — Forensic Risk / Avoid." The score is built from five pillars, each out of 20. The fundamental cash engine scores 6/20, reflecting an ROIC of -35% and an FCF yield of -5.19%; for an investor, this pillar signals that the business is currently consuming rather than generating cash relative to its market value. Whale 13F flow scores 7/20 for institutional accumulation and options positioning, indicating limited institutional support in the source data. Insider conviction scores 3/20 based on SEC Form 4 and Congressional PTR cluster flow, the weakest pillar, suggesting insiders and disclosed officials are not signaling confidence through their trades. Macro regime fit scores 8/20 with a beta of 1.0, meaning the stock moves in line with the broader market and offers no defensive cushion. Forensic balance sheet scores 10/20, combining an Altman Z of 2.5, a Piotroski F of 3/9, and a debt-to-equity ratio of 0.5; this is the strongest pillar but still indicates weak financial quality. Taken together, a prospective investor should view the upside case as dependent on a catalyst-driven recovery rather than on present cash generation, with valuation risk, dilution risk, and sustained losses as the primary tradeoffs.

Per the SEC financials, the company reported net losses in each of the three periods, with no reported revenue or operating income, and gross, operating, and net margins all shown as 0%. Per the market data section, ROIC is -35%, and per the Roarable RQD rating, the Altman Z-Score is 2.5, the Piotroski F-Score is 3/9, and the debt-to-equity ratio is 0.5. The balance sheet posture is described in the source as forensic-risk-flagged, with cash reported only for FY 2024 at $1.3M and debt not available in source data for any period.

Per the recent news section, the dominant event is a $5.6M financing reported across multiple outlets, with coverage describing a PIPE transaction and placement agent warrants. A news item states that billionaire entrepreneur John Paul DeJoria increased his investment in the company, which is tagged as a market-wire item. Several items are tagged as catalysts tied to a breast cancer trial, including reporting that the proceeds are intended to advance Telomir-Zn into a Phase I/II TNBC trial. Other items are tagged as market-wire coverage of seasonal return charts and institutional positioning, with one report referencing a $1 million additional bet by a Patrón co-founder. Risk watch items include the dilution implicit in a PIPE with placement agent warrants and the reliance on financing to fund ongoing losses. Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, there are no butterfly links, and there are no proprietary signals.

• What is the company's cash position and debt level for FY 2025, given that cash and debt are not reported for that period?
• What is the precise dilution impact of the $5.6M PIPE and its placement agent warrants on existing shareholders?
• What is the timeline and funding requirement for the Telomir-Zn Phase I/II TNBC trial?
• What products or revenue model, if any, does the company intend to commercialize?
• What, if any, institutional or insider holdings exist, given that the holders section is empty?